NSC 224249 is an effective dual inhibitor of human CYP17A1 and 5alpha-reductase that effectively blocks the androgen synthesis pathway. It can be used to treat androgen-dependent diseases such as prostate cancer and for research into the regulation of steroid hormone metabolism.
Molekulargewicht:
371.51
Reinheit:
99.42%
CAS Nummer:
[2174-13-2]
Formel:
C23H33NO3
Target-Kategorie:
Reductase
T212764
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten